目的观察经颅磁刺激(TMS)对脑梗死后认知障碍(VCI)的临床疗效及C反应蛋白(CRP)以及纤维蛋白原(Fib)的影响。方法 70例脑梗死后VCI患者,根据治疗方案的不同分为研究组与对照组,各35例。对照组给予血栓通注射液静脉滴注治疗,研究组在对照组的基础上加入TMS治疗。采用蒙特利尔认知评估量表(Mo CA)、AD评估量表-认知分量表(ADAS-Cog)分析治疗前后认知功能变化情况,并对治疗前后患者的CRP、Fib进行比较。结果治疗后,研究组Mo CA、ADAS-Cog评分分别为(23.20±3.49)、(35.22±3.55)分,对照组分别为(21.46±3.54)、(36.91±3.19)分;研究组CRP、Fib水平分别为(6.63±2.85)mg/L、(3.05±0.84)g/L,对照组分别为(8.09±3.22)mg/L、(3.72±0.76)g/L,两组比较差异均有统计学意义(P<0.05)。结论 TMS治疗脑梗死后VCI具有较好的临床效果,值得推广。 Objective To observe the clinical effects of transcranial magnetic stimulation (TMS) on cognitive impairment (VCI) after cerebral infarction and the effects of C reactive protein (CRP) and fibrinogen (Fib). Methods Seventy patients with VCI after cerebral infarction were divided into study group and control group according to the different treatment plans, 35 cases in each group. The control group was given Xueshuantong injection intravenously, and the study group was treated with TMS on the basis of the control group. The changes of cognitive function before and after treatment were analyzed by using Montreal Cognitive Assessment Scale (Mo CA) and AD Assessment Scale-Cognitive Scale (ADAS-Cog), and the levels of CRP and Fib in patients before and after treatment were compared. Results After treatment, the scores of MoCA and ADAS-Cog in the study group were (23.20 ± 3.49) and (35.22 ± 3.55), respectively, and those in the control group were (21.46 ± 3.54) and (36.91 ± 3.19) The levels were (6.63 ± 2.85) mg / L and (3.05 ± 0.84) g / L in the control group and (8.09 ± 3.22) mg / L and (3.72 ± 0.76) g / L in the control group Significance (P <0.05). Conclusions VCI has a good clinical effect after TMS treatment of cerebral infarction and is worth promoting.